Immunotherapy in the matter of immune checkpoint inhibitors (ICIs) such as monoclonal antibodies targeting program death-ligand 1 (PD-L1) and program cell death 1 (PD-1) have reformed the treatment for numerous cancer types and recently, the addition of Atezolizumab to chemotherapy was approved for metastatic and unresectable locally advanced TNBCs [4–7]. The gene discussed is PDCD1; the disease is cancer.